title: [Clinical study on immunotherapy of ovarian cancer with tumor infiltrating lymphocytes].
abstract: OBJECTIVE
  To investigate clinical usage of ovarian tumor infiltrating lymphocytes.
  
  
  METHODS
  Tumor infiltrating lymphocytes (TIL) were isolated by cold digestion method, specimens being taken from: (1) infiltrating node on tumor surface. (2) the tumor proper. (3) the ovarian tissue. A randomized, double-blind study on two groups on ovarian cancer, totally 25 patients was conducted. The first group was given TIL and chemotherapy and the second group was given chemotherapy only.
  
  
  RESULTS
  The yields of infiltrating node on tumor surface were the highest (7.24 x 10(5)), in the tumor proper (2.49 x 10(5)), and in the ovarian tissue the lowest (2.07 x 10(5)). Growth of TIL in nodes on tumor surface increased 3,000 fold, in ovarian tissues and in tumor proper 2500 and 2000 times respectively. The most efficient killing activity was also presented in the infiltrating-nodes on tumor surface. CA125 decreased significantly, tumor regressed in two patients on follow-up by ultrasound, and ascites disappeared completely after one course of chemotherapy and TILs infusion.
  
  
  CONCLUSIONS
  The yields of TIL in infiltrating nodes on tumor surface and their efficiency in killing activity were higher than those in tumor proper and ovarian tissues, and the infiltrating nodes on tumor surface were considered the best sites for obtaining specimens.
authors.affiliation: Ruijin Hospital, Shanghai Second Medical University, Shanghai.
authors.forename: Z
authors.initials: Z
authors.lastname: Hua
authors.forename: J
authors.initials: J
authors.lastname: Lu
authors.forename: H
authors.initials: H
authors.lastname: Li
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy; D018394:CA-125 Antigen / Q000097:blood; D018284:Cystadenocarcinoma, Serous / Q000276:immunology / Q000628:therapy; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016219:Immunotherapy, Adoptive; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D018394:CA-125 Antigen